SOPHiA GENETICS CEO Jurgi Camblong Buys Shares

Jurgi Camblong, the Chief Executive Officer of SOPHiA GENETICS, made a significant move by purchasing 31,940 shares of the company on June 26. The shares were acquired at an average price of $3.16 each, amounting to a total transaction value of approximately $100,930. This transaction was not part of a pre-arranged trading plan, indicating a direct interest in the company's future.

SOPHiA GENETICS SA Stock Down 26.5%

Shares of NasdaqGS:SOPH traded near $5.75 on Tuesday. SOPHiA GENETICS has a market capitalization of about $482.4 million. The company has no meaningful P/E ratio due to its lack of profitability, with a forward P/E of -10.27. Its stock has fluctuated between a 52-week low of $2.81 and a high of $5.94. The stock's 50-day moving average is $5.07, while the 200-day moving average is $4.72. The company maintains a current ratio of 2.06 and a quick ratio of 1.71, with a debt-to-equity ratio of 136.63.

Insider Buying and Selling at SOPHiA GENETICS SA

In addition to Camblong's purchase, there were other insider activities. On June 26, Camblong also sold 50,069 shares at $5.80 under a planned transaction, and 31,940 shares were sold at no cost, indicating a non-market transaction. On June 25, Chief Medical Officer Philippe Menu and Chief Technology Officer Abhimanyu Verma sold shares at $5.50 and $5.51, respectively, under planned transactions.

Analysts Set New Price Targets

Analysts remain optimistic about SOPHiA GENETICS. On June 15, BTIG reiterated a 'buy' rating with a price target of $8. Guggenheim also maintained a 'buy' rating with a $7 target on January 26. The consensus among analysts is a 'strong buy', with an average target price of $8, based on three analyst opinions.

About SOPHiA GENETICS

SOPHiA GENETICS SA is a healthcare technology company based in Rolle, Switzerland. It specializes in cloud-native software that helps analyze and interpret complex data sets in healthcare. The company provides its SOPHiA DDM platform to hospitals, labs, and biopharmaceutical firms across Europe, North America, Latin America, and the Asia-Pacific region. Founded in 2011, SOPHiA GENETICS is led by CEO George A. Cardoza and employs around 415 people.

Bottom Line

Jurgi Camblong's recent purchase of SOPHiA GENETICS shares highlights his confidence in the company's potential. Investors keep a close watch on such insider transactions for insights into a company's prospects. Despite being a backward-looking indicator, these moves can provide valuable context on the company's future direction. SOPHiA GENETICS continues to attract analyst attention with strong 'buy' ratings, reflecting positive sentiment in the market.